Brian Harris

Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial

Xavier Carbonell‐Estrany, Eric A. F. Simões, Ron Dagan et al. · PEDIATRICS · 2009 · 237 citations

Medicine, Infectious Diseases, Pediatrics +17

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial

Katherine L. O’Brien, Aruna Chandran, Robert Weatherholtz et al. · The Lancet Infectious Diseases · 2015 · 190 citations

Medicine, Infectious Diseases, Pediatrics +11

A Randomized Controlled Trial of Motavizumab Versus Palivizumab for the Prophylaxis of Serious Respiratory Syncytial Virus Disease in Children With Hemodynamically Significant Congenital Heart Disease

Timothy F. Feltes, Henry M. Sondheimer, Robert Tulloh et al. · Pediatric Research · 2011 · 110 citations · Full text

Medicine, Pediatrics, Pharmacotherapy +15

Motavizumab Treatment of Infants Hospitalized With Respiratory Syncytial Virus Infection Does Not Decrease Viral Load or Severity of Illness

Octavio Ramilo, Rosanna Lagos, Xavier Sáez‐Llorens et al. · The Pediatric Infectious Disease Journal · 2013 · 87 citations

Pharmacy, Pediatrics, Pharmacotherapy +17

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk Children

Katia Abarca, Elizabeth Jung, Pilar Fernández et al. · The Pediatric Infectious Disease Journal · 2009 · 57 citations

Medicine, Infectious Diseases, Pediatrics +17